Physician profile
Michelle E Greiman
NPI 1982354817
$1,154.96
in general payments reported to CMS, 2019-2025
17 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $674 · 2024: $187 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,052.76 |
| Education | $102.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $285.64 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $177.58 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $127.64 | 2023-2025 | Tremfya |
| Lilly USA, LLC | $119.51 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $69.91 | 2023 | Otezla |
| Arcutis Biotherapeutics, INC. | $58.82 | 2023-2025 | Zoryve |
| Ucb, INC. | $52.59 | 2023-2024 | Bimzelx, Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.74 | 2023-2025 | Spevigo |
| Galderma Laboratories, L.P. | $35.29 | 2024-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $32.79 | 2023 | Ilumya, Winlevi, Absorica Ld |
| Pfizer INC. | $31.90 | 2023 | |
| Blueprint Medicines Corporation | $28.50 | 2023 | |
| Genzyme Corporation | $24.48 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.76 | 2023 | Jublia, Arazlo |
| Verrica Pharmaceuticals INC. | $18.37 | 2023 | Ycanth |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $16.16 | 2023 | Poteligeo |
| Novartis Pharmaceuticals Corporation | $14.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Greiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.